002422 科伦药业
已收盘 05-08 15:00:00
资讯
新帖
简况
东吴证券：给予科伦药业买入评级
证券之星 · 05-05
东吴证券：给予科伦药业买入评级
太平洋：给予科伦药业买入评级，目标价42.0元
证券之星 · 05-01
太平洋：给予科伦药业买入评级，目标价42.0元
科伦药业（002422）2025年一季报简析：净利润减43.07%
证券之星 · 04-30
科伦药业（002422）2025年一季报简析：净利润减43.07%
科伦药业(002422)3月31日股东户数3.34万户，较上期减少16.75%
证券之星 · 04-30
科伦药业(002422)3月31日股东户数3.34万户，较上期减少16.75%
4月30日科伦药业涨9.99%，中欧医疗健康混合A基金重仓该股
证券之星 · 04-30
4月30日科伦药业涨9.99%，中欧医疗健康混合A基金重仓该股
科伦药业涨9.99%，太平洋六日前给出“买入”评级，目标价42.00元
证券之星 · 04-30
科伦药业涨9.99%，太平洋六日前给出“买入”评级，目标价42.00元
科伦药业今日涨停，3家机构专用席位净买入1.32亿元
美港电讯 · 04-30
科伦药业今日涨停，3家机构专用席位净买入1.32亿元
4月30日科伦药业（002422）涨停分析：仿制药走强、业绩增长、新药突破驱动
证券之星 · 04-30
4月30日科伦药业（002422）涨停分析：仿制药走强、业绩增长、新药突破驱动
异动快报：科伦药业（002422）4月30日14点19分触及涨停板
证券之星 · 04-30
异动快报：科伦药业（002422）4月30日14点19分触及涨停板
科伦药业上涨9.02%，报35.89元/股
金融界 · 04-30
科伦药业上涨9.02%，报35.89元/股
A股创新药概念股集体走强，科伦药业涨超6%，恒瑞医药涨超3%
格隆汇 · 04-30
A股创新药概念股集体走强，科伦药业涨超6%，恒瑞医药涨超3%
A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨
美港电讯 · 04-30
A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨
科伦药业(002422.SZ)发布一季度业绩，归母净利润5.84亿元，下降43.07%
智通财经 · 04-29
科伦药业(002422.SZ)发布一季度业绩，归母净利润5.84亿元，下降43.07%
图解科伦药业一季报：第一季度单季净利润同比减43.07%
证券之星 · 04-29
图解科伦药业一季报：第一季度单季净利润同比减43.07%
仿制药概念股回调，科伦药业跌逾5%，华东医药、海思科、山河药辅跌逾4%。
金融界 · 04-25
仿制药概念股回调，科伦药业跌逾5%，华东医药、海思科、山河药辅跌逾4%。
科伦药业（002422）2024年年报简析：营收净利润同比双双增长
证券之星 · 04-24
科伦药业（002422）2024年年报简析：营收净利润同比双双增长
一季度提高两只医药基金股票仓位，中欧基金葛兰加仓科伦药业、百利天恒
澎湃新闻 · 04-22
一季度提高两只医药基金股票仓位，中欧基金葛兰加仓科伦药业、百利天恒
摩根基金杜猛：一季度提高股票仓位，2025年有很大可能是转折之年
美港电讯 · 04-22
摩根基金杜猛：一季度提高股票仓位，2025年有很大可能是转折之年
科伦药业最新公告：子公司创新ADC药物SKB518新药临床试验申请获美国FDA批准
证券之星 · 04-21
科伦药业最新公告：子公司创新ADC药物SKB518新药临床试验申请获美国FDA批准
科伦药业：子公司SKB518新药临床试验申请获FDA批准
美港电讯 · 04-21
科伦药业：子公司SKB518新药临床试验申请获FDA批准
加载更多
公司概况
公司名称：
四川科伦药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。
发行价格：
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":34.02,"timestamp":1746687837000,"preClose":34.65,"halted":0,"volume":13477017,"delay":0,"changeRate":-0.0182,"floatShares":1306000000,"shares":1598000000,"eps":1.5607,"marketStatus":"已收盘","change":-0.63,"latestTime":"05-08 15:00:00","open":34.55,"high":34.65,"low":33.97,"amount":461000000,"amplitude":0.0196,"askPrice":34.03,"askSize":42,"bidPrice":34.02,"bidSize":155,"shortable":0,"etf":0,"ttmEps":1.5607,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746754200000},"marketStatusCode":5,"adr":0,"adjPreClose":34.65,"symbolType":"stock","openAndCloseTimeList":[[1746667800000,1746675000000],[1746680400000,1746687600000]],"highLimit":38.12,"lowLimit":31.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.4,"roa":"--","peRate":21.797911,"roe":"2.56%","epsLYR":1.86,"committee":0.567516,"marketValue":54366000000,"turnoverRate":0.0103,"status":1,"floatMarketCap":44426000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2533538883","title":"东吴证券：给予科伦药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2533538883","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533538883?lang=zh_cn&edition=full","pubTime":"2025-05-05 22:04","pubTimestamp":1746453872,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,张翀翯近期对科伦药业进行研究并发布了研究报告《2025年一季报点评：高基数扰动Q1，创新管线兑现+国际化打开长期空间》，给予科伦药业买入评级。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为45.14。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050500003141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","601555"],"gpt_icon":0},{"id":"2532003941","title":"太平洋：给予科伦药业买入评级，目标价42.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532003941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532003941?lang=zh_cn&edition=full","pubTime":"2025-05-01 21:56","pubTimestamp":1746107790,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫近期对科伦药业进行研究并发布了研究报告《低谷期已过，全年有望迎来环比持续改善》，给予科伦药业买入评级，目标价42.0元。2025年第一季度公司实现营业收入43.90亿元，同比下滑29.42%，利润端归母净利润为5.84亿元，同比下滑43.07%，扣非后归母净利润为5.64亿元，同比下滑43.10%。最新盈利预测明细如下：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为44.48。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100009016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","002422"],"gpt_icon":0},{"id":"2532187340","title":"科伦药业（002422）2025年一季报简析：净利润减43.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532187340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532187340?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:53","pubTimestamp":1746053629,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科伦药业发布2025年一季报。根据财报显示，科伦药业净利润减43.07%。截至本报告期末，公司营业总收入43.9亿元，同比下降29.42%，归母净利润5.84亿元，同比下降43.07%。去年的净利率为15.41%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100005466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2531086183","title":"科伦药业(002422)3月31日股东户数3.34万户，较上期减少16.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531086183","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531086183?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:50","pubTimestamp":1746006637,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科伦药业披露，截至2025年3月31日公司股东户数为3.34万户，较12月31日减少6720.0户，减幅为16.75%。在化学制药行业个股中，科伦药业股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.2万户。从股价来看，2024年12月31日至2025年3月31日，科伦药业区间涨幅为7.68%，在此期间股东户数减少6720.0户，减幅为16.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000036585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","BK0060","002422","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2531702912","title":"4月30日科伦药业涨9.99%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531702912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531702912?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:37","pubTimestamp":1746002245,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日科伦药业涨9.99%，收盘报36.21元，换手率3.22%，成交量41.98万手，成交额14.46亿元。重仓科伦药业的前十大公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为44.48。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共133家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0239","002422","LU2148510915.USD","BK0060","LU1064131003.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2531029157","title":"科伦药业涨9.99%，太平洋六日前给出“买入”评级，目标价42.00元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531029157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531029157?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:37","pubTimestamp":1746002233,"startTime":"0","endTime":"0","summary":"今日科伦药业涨9.99%，收盘报36.21元。2025年4月24日，太平洋研究员周豫发布了对科伦药业的研报《利润端保持高速增长，销售费用率持续下降》，该研报对科伦药业给出“买入”评级，认为其目标价为42.0元，现价距离目标价尚有15.99%的涨幅空间。归母净利润为34.64/40.50/46.16亿元，同比增长17.99%/16.92%/13.97%。考虑公司院内集采影响边际加速弱化，创新药持续贡献增量，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000033219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","601099"],"gpt_icon":0},{"id":"2531701720","title":"科伦药业今日涨停，3家机构专用席位净买入1.32亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531701720","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531701720?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:27","pubTimestamp":1746001646,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","BK0060","002422"],"gpt_icon":0},{"id":"2531058207","title":"4月30日科伦药业（002422）涨停分析：仿制药走强、业绩增长、新药突破驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2531058207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531058207?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:34","pubTimestamp":1745998453,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业4月30日涨停收盘，收盘价36.21元。今日科伦药业涨停的可能因素有：1）仿制药板块整体走强带动相关个股活跃；2）公司2024年报显示净利润同比增长19.53%，业绩稳健增长提振市场信心；3）控股子公司科伦博泰研发的SKB107新药临床试验获批，创新药管线突破引发关注；4）公司涉及合成生物、医疗器械等热点概念，叠加分拆上市预期增强估值弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000026835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2148510915.USD","BK0060","002422","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2531774996","title":"异动快报：科伦药业（002422）4月30日14点19分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2531774996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531774996?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:20","pubTimestamp":1745994045,"startTime":"0","endTime":"0","summary":"证券之星4月30日盘中消息，14点19分科伦药业触及涨停板。目前价格36.21，上涨9.99%。其所属行业化学制药目前上涨。领涨股为汉商集团。该股为健康中国，新冠病毒防治，幽门螺杆菌概念概念热股，当日健康中国概念上涨1.31%，新冠病毒防治概念上涨1.27%，幽门螺杆菌概念概念上涨1.12%。4月30日的资金流向数据方面，主力资金净流入6587.46万元，占总成交额7.37%，游资资金净流出90.65万元，占总成交额0.1%，散户资金净流出6496.81万元，占总成交额7.27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000025342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064130708.USD","002422","BK0239","LU1064131003.USD","BK0060"],"gpt_icon":0},{"id":"2531677122","title":"科伦药业上涨9.02%，报35.89元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531677122","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531677122?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:05","pubTimestamp":1745993119,"startTime":"0","endTime":"0","summary":"4月30日，科伦药业盘中上涨9.02%，截至14:05，报35.89元/股，成交11.24亿元，换手率2.53%，总市值573.54亿元。资料显示，四川科伦药业股份有限公司位于成都市新都卫星城工业开发区南二路，公司专注于输液产品、抗生素和创新药物的研发与制造，致力于全球市场的战略布局。截至9月30日，科伦药业股东户数3.38万，人均流通股3.88万股。2024年1月-9月，科伦药业实现营业收入167.89亿元，同比增长6.64%；归属净利润24.71亿元，同比增长25.85%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30140550037820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0060","002422","LU1064130708.USD","LU2148510915.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2531392776","title":"A股创新药概念股集体走强，科伦药业涨超6%，恒瑞医药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392776","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531392776?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:16","pubTimestamp":1745990168,"startTime":"0","endTime":"0","summary":"格隆汇4月30日｜A股市场创新药概念股集体走强，其中，凯因科技涨超7%，科伦药业、益方生物涨超6%，金城医药涨超5%，北陆药业、艾力斯、德源药业、艾迪药业、苑东生物、华东医药、皓元医药、万邦医药、恒瑞医药涨超3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430131616974b186f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430131616974b186f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002422","159992","BK0196","LU1064130708.USD","BK0060","LU1064131003.USD","600276","LU0405327494.USD","399300","159982","BK0188","LU0405327148.USD","BK0183","BK0012","LU2148510915.USD","LU2488822045.USD","LU1328615791.USD","LU1969619763.USD","LU2328871848.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2531735757","title":"A股创新药概念持续走强，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制药、华东医药、恒瑞医药等涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735757","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531735757?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:13","pubTimestamp":1745990033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002422","688382","159992","ONC","BK0132","LU0588546209.SGD","BK1588","BK1574","688428","BK0028","LU0405327148.USD","600276","BK0187","06978","BK0175","BK0209","BK1161","LU1064131003.USD","LU0405327494.USD","BK0196","BK4139","BK1500","688266","399300","BK0183","LU2148510915.USD","BK0012","BK1583","LU1969619763.USD","BK0188","688235","BK0239","LU0307460666.USD","06160","LU1328615791.USD","LU2488822045.USD","LU2328871848.SGD","000963","LU1064130708.USD","BK0060","159982","09969"],"gpt_icon":0},{"id":"2531755993","title":"科伦药业(002422.SZ)发布一季度业绩，归母净利润5.84亿元，下降43.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531755993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531755993?lang=zh_cn&edition=full","pubTime":"2025-04-29 22:15","pubTimestamp":1745936110,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)发布2025年第一季度报告，该公司营业收入为43.9亿元，同比减少29.42%。归属于上市公司股东的净利润为5.84亿元，同比减少43.07%。归属于上市公司股东的扣除非经常性损益的净利润为5.64亿元，同比减少43.10%。基本每股收益为0.37元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002422"],"gpt_icon":0},{"id":"2531732782","title":"图解科伦药业一季报：第一季度单季净利润同比减43.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531732782?lang=zh_cn&edition=full","pubTime":"2025-04-29 19:45","pubTimestamp":1745927110,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业2025年一季报显示，公司主营收入43.9亿元，同比下降29.42%；归母净利润5.84亿元，同比下降43.07%；扣非净利润5.64亿元，同比下降43.1%；负债率27.48%，投资收益6131.44万元，财务费用412.68万元，毛利率48.67%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"acf37690706a73438284a9e794ae3947","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900037599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2530948029","title":"仿制药概念股回调，科伦药业跌逾5%，华东医药、海思科、山河药辅跌逾4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530948029","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530948029?lang=zh_cn&edition=full","pubTime":"2025-04-25 10:10","pubTimestamp":1745547028,"startTime":"0","endTime":"0","summary":"仿制药概念股回调，科伦药业跌逾5%，华东医药、海思科、山河药辅跌逾4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25101049864042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0175","LU2328871848.SGD","300452","000963","002422","BK0028","BK0060","BK0187","LU2148510915.USD","BK0177","BK0132","BK0196","BK0209","BK0033","BK0239","LU1064131003.USD","LU1064130708.USD","BK0077","002653","LU1969619763.USD","BK0183","BK0188"],"gpt_icon":0},{"id":"2530992660","title":"科伦药业（002422）2024年年报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2530992660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530992660?lang=zh_cn&edition=full","pubTime":"2025-04-25 06:13","pubTimestamp":1745532791,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科伦药业发布2024年年报。根据财报显示，科伦药业营收净利润同比双双增长。截至本报告期末，公司营业总收入218.12亿元，同比上升1.67%，归母净利润29.36亿元，同比上升19.53%。按单季度数据看，第四季度营业总收入50.24亿元，同比下降12.03%，第四季度归母净利润4.65亿元，同比下降5.65%。投资活动产生的现金流量净额变动幅度为46.02%,原因:理财产品的净投资额同比减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500006573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2529877815","title":"一季度提高两只医药基金股票仓位，中欧基金葛兰加仓科伦药业、百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2529877815","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529877815?lang=zh_cn&edition=full","pubTime":"2025-04-22 22:33","pubTimestamp":1745332380,"startTime":"0","endTime":"0","summary":"4月22日，中欧基金投资总监葛兰在管基金披露了2025年一季报。其中，科伦药业首次进入该基金的持仓前十。拉长时间来看，中欧医疗健康于2018年清仓卖出科伦药业之后，又于2024年重新买回。此外，葛兰还小幅度加仓了泰格医药、爱尔眼科。截至2025年一季度末，该基金在管规模为82亿元，较此前2024年末增长10.17亿元，是葛兰旗下规模第二大的基金产品。展望二季度，葛兰仍旧看好创新药持续突破、消费医疗复苏与产业链关键环节国产化等方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422224124a46299e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422224124a46299e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","LU1064130708.USD","160635","002422","BK0060","LU2148510915.USD","BK0239","LU1064131003.USD"],"gpt_icon":0},{"id":"2529328359","title":"摩根基金杜猛：一季度提高股票仓位，2025年有很大可能是转折之年","url":"https://stock-news.laohu8.com/highlight/detail?id=2529328359","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529328359?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:46","pubTimestamp":1745311580,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1328615791.USD","LU1997245094.SGD","LU1934453819.USD","BK1161","SG9999014674.SGD","LU1979443071.USD","300476","BK1574","LU2495084118.USD","BK0125","159542","LU1997244956.HKD","BK0196","399300","002422","BK0155","BK0182","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","06978","603799","603501","BK0077","LU1997245177.USD","BK0214","BK0233","159982","BK0197","BK0060","159992","BK0239"],"gpt_icon":0},{"id":"2529710518","title":"科伦药业最新公告：子公司创新ADC药物SKB518新药临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2529710518","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529710518?lang=zh_cn&edition=full","pubTime":"2025-04-21 18:50","pubTimestamp":1745232601,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司控股子公司四川科伦博泰生物医药股份有限公司已获得美国FDA批准启动其创新抗体偶联药物（ADC）药物SKB518的临床研究。SKB518是一款由科伦博泰针对特定靶点生物学特点研发的新型ADC药物，拟用于治疗晚期实体瘤。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042100024673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1576","03347","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0060","BK1141","BK1583","002422"],"gpt_icon":0},{"id":"2529871354","title":"科伦药业：子公司SKB518新药临床试验申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2529871354","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529871354?lang=zh_cn&edition=full","pubTime":"2025-04-21 18:41","pubTimestamp":1745232084,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","IND.AU","002422","CDE","BK4017","BK7095","BK4080","BK1576","BK0060","BK1141","ADC.AU","LU1064130708.USD","ADC","BK0239","03347","BK7050","LU2148510915.USD","LU1064131003.USD","CDE.AU","BK4231"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746742538048,"stockEarnings":[{"period":"1week","weight":-0.0605},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.2211},{"period":"6month","weight":0.0116},{"period":"1year","weight":0.0451},{"period":"ytd","weight":0.1367}],"compareEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":0.0656},{"period":"3month","weight":0.0146},{"period":"6month","weight":-0.0291},{"period":"1year","weight":0.0714},{"period":"ytd","weight":0.0001}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33389人(较上一季度减少16.75%)","perCapita":"39110股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}